Beaufort Securities restated their speculative buy rating on shares of Tiziana Life Sciences PLC (LON:TILS) in a report issued on Friday morning.

Tiziana Life Sciences PLC (LON:TILS) traded up 0.30% during midday trading on Friday, reaching GBX 185.55. 1,309 shares of the company’s stock were exchanged. The company’s market cap is GBX 172.16 million. The company has a 50 day moving average price of GBX 190.69 and a 200 day moving average price of GBX 158.97. Tiziana Life Sciences PLC has a 12 month low of GBX 91.35 and a 12 month high of GBX 232.95.

Tiziana Life Sciences PLC Company Profile

Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. The Company is engaged in the research and development of biotechnological and pharmaceutical products. Its subsidiary, Tiziana Pharma Limited (TPL), is formed as a vehicle to acquire and exploit certain intellectual property in biotechnology, specifically a program focused on metastatic breast cancer.

Receive News & Stock Ratings for Tiziana Life Sciences PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences PLC and related stocks with our FREE daily email newsletter.